Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Sells 660 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 660 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $25.46, for a total value of $16,803.60. Following the completion of the sale, the chief financial officer now directly owns 120,960 shares in the company, valued at approximately $3,079,641.60. This represents a 0.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Troy Wichterman also recently made the following trade(s):

• On Wednesday, February 12th, Troy Wichterman sold 159 shares of BioLife Solutions stock. The stock was sold at an average price of $26.54, for a total value of $4,219.86.
• On Monday, January 6th, Troy Wichterman sold 987 shares of BioLife Solutions stock. The shares were sold at an average price of $27.02, for a total value of $26,668.74.

BioLife Solutions Stock Up 5.7 %

NASDAQ:BLFS opened at $26.25 on Thursday. The stock’s fifty day moving average price is $26.67 and its two-hundred day moving average price is $25.48. The company has a market cap of $1.22 billion, a price-to-earnings ratio of -24.76 and a beta of 1.91. BioLife Solutions, Inc. has a 52-week low of $14.84 and a 52-week high of $29.55. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78.

BioLife Solutions (NASDAQ:BLFS) last issued its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The company had revenue of $22.71 million during the quarter, compared to analysts’ expectations of $21.73 million. During the same quarter in the previous year, the company posted ($0.21) EPS. On average, analysts anticipate that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Analyst Ratings Changes

BLFS has been the subject of a number of recent research reports. HC Wainwright dropped their price objective on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Northland Securities lifted their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday, January 8th. KeyCorp raised their target price on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Benchmark reiterated a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a research report on Thursday, December 19th. Finally, Craig Hallum increased their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $29.43.

Institutional Trading of BioLife Solutions

Several hedge funds have recently added to or reduced their stakes in BLFS. D.A. Davidson & CO. raised its holdings in shares of BioLife Solutions by 1.3% during the fourth quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider’s stock worth $1,069,000 after acquiring an additional 519 shares during the period. Stifel Financial Corp boosted its position in BioLife Solutions by 5.4% during the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after acquiring an additional 670 shares during the last quarter. 1620 Investment Advisors Inc. lifted its position in shares of BioLife Solutions by 41.7% in the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock worth $60,000 after purchasing an additional 675 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in BioLife Solutions by 27.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider’s stock worth $117,000 after acquiring an additional 950 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC acquired a new position in BioLife Solutions during the fourth quarter valued at approximately $26,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.